47 CHEMICALS KNOWLEDGE HUB Issue 1 / July 2025 billion by 2032 from USD 28.58 billion in 2024, at a CAGR of 33.6% during the forecast period. The major factors driving the growth of this segment are ease and convenience of administration, leading to higher adherence. Ecosystem analysis The GLP-1 analogues market ecosystem comprises raw material suppliers providing essential components like consumables and instrument manufacturers offering media, reagents, and end users such as hospitals & specialty clinics, long-term care facilities, and home care settings. Manufacturers develop and distribute GLP-1 analogues while navigating regulations set by bodies like the FDA and EMA, ensuring quality and compliance throughout the supply chain. This intricate network facilitates the production, research, and development of biopharmaceuticals and enables advancements in novel antidiabetics and weight management drugs. Glp-1 analogues market: ecosystem analysis Regulatory landscape The regulatory landscape for the GLP-1 analogues market is characterized by stringent guidelines and oversights to ensure the safety, efficacy, and quality of GLP-1 receptor agonists for indications such as diabetes and obesity. Regulatory bodies such as the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regional agencies are important in setting guidelines and requirements for developing, manufacturing, and commercializing GLP-1 analogues. The GLP-1 receptor agonists (GLP-1 RAs) are primarily approved for treating type 2 diabetes mellitus and obesity. GLP1 receptor agonists mimic the action of the endogenous hormone GLP-1, which regulates insulin secretion from pancreatic B-cells. This is crucial for maintaining glucose homeostasis in patients with type 2 diabetes mellitus. As the market for GLP-1 drugs is predominantly concentrated in the US and Europe, the key regulatory authorities reviewing pipeline product trials are the US FDA and the European Medicines Agency (EMA). The US FDA has published a document named ‘Guidance for Industry: Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention,’ which provides comprehensive recommendations for developing new drugs and biologics to treat and prevent diabetes mellitus. The document emphasizes factors such as efficacy endpoints, patient populations to be considered, and safety assessment considerations, among others. MarketsandMarketsTM INNOVATION & TRENDS
RkJQdWJsaXNoZXIy MjY2OTA4MA==